Literature DB >> 16117757

Brief report: Free prostate-specific antigen test utilization. Consistency with guidelines.

Brian R Jackson1, William L Roberts.   

Abstract

BACKGROUND: The American Cancer Society and American Urologic Association recommend prostate cancer screening for average-risk men between the ages of 50 and 75 years using digital rectal examination and prostate-specific antigen (PSA) testing. Measuring the percent free PSA may improve test specificity for detecting prostate cancer when the total PSA is between 2.5 and 10 ng/mL.
OBJECTIVE: To assess whether free PSA testing practices are consistent with published screening guidelines.
DESIGN: Retrospective analysis of free PSA testing performed by a national reference laboratory between October 1, 2003 and September 30, 2004. MEASUREMENTS: Free PSA and total PSA results and the age of the patient at testing.
RESULTS: Over 24% of free PSA tests were performed on patients greater than 75 years of age, and 38% were performed on patients with a total PSA either less than 2.5 ng/mL or greater than 10.0 ng/mL.
CONCLUSIONS: A substantial proportion of free PSA tests performed in a national reference laboratory appeared to be inconsistent with existing screening guidelines. This raises concern that some of these patients may have received inappropriate diagnostic workup and/or therapy, resulting in excess medical costs and potential harms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117757      PMCID: PMC1490212          DOI: 10.1111/j.1525-1497.2005.0181.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  14 in total

1.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer.

Authors:  P Carroll; C Coley; D McLeod; P Schellhammer; G Sweat; J Wasson; A Zietman; I Thompson
Journal:  Urology       Date:  2001-02       Impact factor: 2.649

2.  Appropriateness of prostate-specific antigen testing.

Authors:  H T Poteat; P Chen; K R Loughlin; J W Winkelman; R Allada; N Ma'luf; M J Tanasijevic; D W Bates
Journal:  Am J Clin Pathol       Date:  2000-03       Impact factor: 2.493

3.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

4.  American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001--testing for early lung cancer detection.

Authors:  R A Smith; A C von Eschenbach; R Wender; B Levin; T Byers; D Rothenberger; D Brooks; W Creasman; C Cohen; C Runowicz; D Saslow; V Cokkinides; H Eyre
Journal:  CA Cancer J Clin       Date:  2001 Jan-Feb       Impact factor: 508.702

5.  Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels.

Authors:  R M Hoffman; D L Clanon; B Littenberg; J J Frank; J C Peirce
Journal:  J Gen Intern Med       Date:  2000-10       Impact factor: 5.128

6.  Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.

Authors:  C M Coley; M J Barry; C Fleming; M C Fahs; A G Mulley
Journal:  Ann Intern Med       Date:  1997-03-15       Impact factor: 25.391

7.  Prostate-specific antigen screening in elderly men.

Authors:  Grace Lu-Yao; Therese A Stukel; Siu-Long Yao
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?

Authors:  Brenda E Sirovich; Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2003-03-19       Impact factor: 56.272

10.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

Authors:  P H Gann; C H Hennekens; M J Stampfer
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.